Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Mezagitamab |
Trade Name | |
Synonyms | TAK079|TAK 079|TAK-079 |
Drug Descriptions |
Mezagitamab (TAK-079) is a monoclonal antibody that targets CD38, which has potential cytolytic effects against CD38-expressing cells (J Immunol May 1, 2017, 198 (1 Supplement) 224.20, PMID: 32045493). |
DrugClasses | CD38 Antibody 20 |
CAS Registry Number | 2227490-52-8 |
NCIT ID | C148078 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bortezomib + Dexamethasone + Lenalidomide + Mezagitamab | Bortezomib Dexamethasone Lenalidomide Mezagitamab | 0 | 1 |
Dexamethasone + Lenalidomide + Mezagitamab | Dexamethasone Lenalidomide Mezagitamab | 0 | 1 |
Dexamethasone + Mezagitamab + Pomalidomide | Dexamethasone Mezagitamab Pomalidomide | 0 | 1 |
Mezagitamab | Mezagitamab | 0 | 1 |
Mezagitamab + Subasumstat | Mezagitamab Subasumstat | 0 | 1 |